Hainan Huluwa Pharmaceutical Group Co., Ltd.
SSE:605199.SS
9.59 (CNY) • At close June 6, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) CNY.
| 2025 Q1 | 2024 Q4 | 2024 Q3 | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 Q3 | 2023 Q2 | 2023 Q1 | 2022 Q4 | 2022 Q3 | 2022 Q2 | 2022 Q1 | 2021 Q4 | 2021 Q3 | 2021 Q2 | 2021 Q1 | 2020 Q4 | 2020 Q3 | 2020 Q2 | 2020 Q1 | 2019 Q4 | 2019 Q3 | 2019 Q2 | 2019 Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 336.827 | 380.959 | 343.669 | 412.009 | 430.405 | 627.21 | 363.993 | 386.718 | 527.262 | 458.445 | 323.143 | 334.293 | 399.166 | 443.252 | 279.337 | 322.719 | 308.485 | 348.565 | 237.587 | 316.828 | 258.725 | 437.24 | 257.877 | 335.007 | 275.794 |
| Cost of Revenue
| 204.76 | 221.446 | 123.02 | 200.952 | 224.817 | 280.897 | 182.285 | 194.199 | 242.45 | 244.739 | 127.99 | 126.82 | 139.033 | 165.043 | 106.403 | 141.05 | 132.6 | 144.528 | 90.617 | 115.041 | 93.467 | 169.488 | 95.323 | 125.692 | 106.283 |
| Gross Profit
| 132.067 | 159.513 | 220.65 | 211.057 | 205.588 | 346.313 | 181.708 | 192.518 | 284.811 | 213.706 | 195.153 | 207.473 | 260.133 | 278.208 | 172.933 | 181.669 | 175.886 | 204.037 | 146.97 | 201.787 | 165.258 | 267.752 | 162.553 | 209.315 | 169.512 |
| Gross Profit Ratio
| 0.392 | 0.419 | 0.642 | 0.512 | 0.478 | 0.552 | 0.499 | 0.498 | 0.54 | 0.466 | 0.604 | 0.621 | 0.652 | 0.628 | 0.619 | 0.563 | 0.57 | 0.585 | 0.619 | 0.637 | 0.639 | 0.612 | 0.63 | 0.625 | 0.615 |
| Reseach & Development Expenses
| 10.328 | 65.681 | 17.845 | 19.044 | 19.339 | 43.581 | 20.252 | 10.479 | 19.605 | 17.499 | 25.909 | 27.465 | 34.79 | 44.805 | 14.817 | 27.12 | 13.69 | 19.868 | 10.849 | 11.601 | 9.344 | 18.032 | 14.434 | 6.315 | 12.88 |
| General & Administrative Expenses
| 26.769 | -47.874 | 70.319 | -12.43 | 23.469 | -44.889 | 57.031 | -14.167 | 27.825 | -39.664 | 42.752 | -6.047 | 18.246 | -21.881 | 37.376 | -7.043 | 14.784 | -18.348 | 16.024 | -4.634 | 14.08 | -19.999 | 15.223 | 15.279 | 13.945 |
| Selling & Marketing Expenses
| 58.474 | 62.353 | 219.61 | 142.025 | 126.281 | 222.073 | 111.763 | 134.894 | 169.478 | 161.176 | 133.619 | 131.148 | 158.329 | 202.135 | 104.209 | 124.161 | 115.077 | 126.47 | 102.476 | 133.126 | 113.223 | 164.832 | 117.061 | 152.668 | 115.093 |
| SG&A
| 85.243 | 14.479 | 289.929 | 156.707 | 149.75 | 177.183 | 168.794 | 120.728 | 197.304 | 121.511 | 176.371 | 125.1 | 176.574 | 180.254 | 141.585 | 117.119 | 129.862 | 108.121 | 118.5 | 128.492 | 127.303 | 144.833 | 132.284 | 167.947 | 129.039 |
| Other Expenses
| 12.723 | 235.895 | -86.715 | -2.737 | 0.56 | -0.672 | -0.116 | 0.005 | -4.125 | 54.486 | -25.178 | 18.449 | 0.024 | 16.136 | -0.522 | -0.023 | -0.483 | 1.029 | -0.081 | 0.045 | -0.777 | 0.629 | 0.151 | -0.061 | -0.028 |
| Operating Expenses
| 108.295 | 316.055 | 221.064 | 178.488 | 165.91 | 288.211 | 154.963 | 158.979 | 212.783 | 193.496 | 177.101 | 171.014 | 211.388 | 292.082 | 135.6 | 153.24 | 142.212 | 162.688 | 103.655 | 159.95 | 137.821 | 182.33 | 148.005 | 177.533 | 142.881 |
| Operating Income
| 23.772 | -156.542 | 1.732 | 32.569 | 35.644 | 33.352 | 16.618 | 28.224 | 58.743 | 15.901 | 12.981 | 27.591 | 40.149 | -20.37 | 29.996 | 27.62 | 29.311 | 40.646 | 39.741 | 31.075 | 22.711 | 80.298 | 13.897 | 26.326 | 21.031 |
| Operating Income Ratio
| 0.071 | -0.411 | 0.005 | 0.079 | 0.083 | 0.053 | 0.046 | 0.073 | 0.111 | 0.035 | 0.04 | 0.083 | 0.101 | -0.046 | 0.107 | 0.086 | 0.095 | 0.117 | 0.167 | 0.098 | 0.088 | 0.184 | 0.054 | 0.079 | 0.076 |
| Total Other Income Expenses Net
| -0.045 | -1.613 | -0.43 | -0.023 | -1.956 | -0.672 | -0.116 | 0.005 | -0.661 | 1.61 | -0.189 | -0.011 | -0.805 | 16.136 | -0.522 | -0.023 | -0.483 | 1.029 | -0.081 | 0.045 | -0.777 | 0.629 | 0.151 | -0.061 | -0.028 |
| Income Before Tax
| 23.727 | -158.156 | 1.301 | 59.55 | 36.204 | 32.68 | 16.502 | 28.23 | 58.082 | 17.512 | 12.792 | 27.581 | 39.343 | -4.235 | 29.473 | 27.597 | 28.828 | 41.674 | 39.66 | 31.12 | 21.934 | 80.927 | 14.048 | 26.264 | 21.002 |
| Income Before Tax Ratio
| 0.07 | -0.415 | 0.004 | 0.145 | 0.084 | 0.052 | 0.045 | 0.073 | 0.11 | 0.038 | 0.04 | 0.083 | 0.099 | -0.01 | 0.106 | 0.086 | 0.093 | 0.12 | 0.167 | 0.098 | 0.085 | 0.185 | 0.054 | 0.078 | 0.076 |
| Income Tax Expense
| -0.764 | -1.942 | -6.242 | 7.341 | 6.042 | 2.873 | -3.127 | 5.467 | 17.66 | 4.22 | -1.384 | 0.199 | 9.451 | 2.29 | 4.022 | 0.652 | 5.144 | -4.753 | 7.099 | 5.601 | 4.94 | 7.948 | 7.342 | 2.502 | 4.12 |
| Net Income
| 24.347 | -156.908 | 5.134 | 49.719 | 29.032 | 28.996 | 16.137 | 20.805 | 40.56 | 13.796 | 14.26 | 27.711 | 29.914 | -5.223 | 25.446 | 28.215 | 23.7 | 46.428 | 32.561 | 25.519 | 16.995 | 72.979 | 6.706 | 23.762 | 16.882 |
| Net Income Ratio
| 0.072 | -0.412 | 0.015 | 0.121 | 0.067 | 0.046 | 0.044 | 0.054 | 0.077 | 0.03 | 0.044 | 0.083 | 0.075 | -0.012 | 0.091 | 0.087 | 0.077 | 0.133 | 0.137 | 0.081 | 0.066 | 0.167 | 0.026 | 0.071 | 0.061 |
| EPS
| 0.06 | -0.391 | 0.013 | 0.12 | 0.07 | 0.082 | 0.04 | 0.052 | 0.1 | 0.035 | 0.033 | 0.065 | 0.07 | -0.014 | 0.064 | 0.071 | 0.06 | 0.12 | 0.081 | 0.075 | 0.05 | 0.21 | 0.019 | 0.07 | 0.05 |
| EPS Diluted
| 0.06 | -0.391 | 0.013 | 0.12 | 0.07 | 0.082 | 0.04 | 0.052 | 0.1 | 0.035 | 0.033 | 0.065 | 0.07 | -0.014 | 0.064 | 0.071 | 0.06 | 0.12 | 0.081 | 0.075 | 0.05 | 0.21 | 0.019 | 0.07 | 0.05 |
| EBITDA
| 33.694 | -148.158 | 10.065 | 80.856 | 53.775 | 35.482 | 26.062 | 47.012 | 76.008 | 34.519 | 30.203 | 44.573 | 56.808 | 0.85 | 47.753 | 40.883 | 41.845 | 55.183 | 52.116 | 43.564 | 33.586 | 94.853 | 24.956 | 30.369 | 29.907 |
| EBITDA Ratio
| 0.1 | -0.389 | 0.029 | 0.196 | 0.125 | 0.057 | 0.072 | 0.122 | 0.144 | 0.075 | 0.093 | 0.133 | 0.142 | 0.002 | 0.171 | 0.127 | 0.136 | 0.158 | 0.219 | 0.138 | 0.13 | 0.217 | 0.097 | 0.091 | 0.108 |